Floatz logo

Tak-659

Diffuse Large B-Cell Lymphoma

Calithera Biosciences, IncPhase 2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
73/ 100

Competitive context

252 Active assets in the Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Tak-659 is also rated in:

diffuse large B-cell lymphoma germinal center B-cell typeDormant
C
Indicative ·
33 / 100
View asset →
high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangementDormant
C
Indicative ·
33 / 100
View asset →
diffuse large B-cell lymphoma activated B-cell typeDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →